Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 38

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 38
---
DiamiR’s CLIA -certified, CAP -accreditedlaboratory is staffed with experienced assay development executives and staff with years of experience in developing molecular and biomarker testing solutions; this team validated and launched the first commercially available miRNA clinical test in oncology (thyroid cancer) and will apply their know -howto help Aptorum in its clinical development programs; •The combination with Aptorum Group will allow DiamiR to grow as part of a global company with broader network of experts and key opinion leaders; •Business combination with a publicly listed company is expected to provide DiamiR with access to additional resources, including capital, to advance its product candidates for brain health, cancer and inflammatory diseases and to create value to shareholders; •DiamiR’s lead program is focused on detecting, monitoring, and predicting risk of progression of brain health indications, such as mild cognitive impairment and Alzheimer’s disease; there is a huge need in these testing solutions and a public company platform is better suited for this objective. After giving consideration to these and other factors (including such factors as mentioned above for Aptorum’s reasoning for entering the merger), DiamiR’s board of directors approved the Merger, which the DiamiR board of directors believes better positions DiamiR for long -termsuccess. 6 Interests of Aptorum Directors and Officers in the Merger In considering the recommendation of the Aptorum Board with respect to issuing shares of Aptorum Delaware common stock in the Merger and the other matters to be acted upon by the Aptorum shareholders at the Special Meeting, the Aptorum shareholders should be aware that Aptorum directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Aptorum shareholders generally. These interests may present Aptorum directors and executive officers with actual or potential conflicts of interest. For example, Aptorum’s directors and officers will be eligible for continued indemnification and continued coverage under directors’ and officers’ liability insurance after the Closing and pursuant to the terms of the Merger Agreement. As of July14, 2025, Aptorum’s directors and executive officers owned, in the aggregate, 36.32% of the outstanding shares of Aptorum’s Class A ordinary shares. The Aptorum Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Aptorum shareholders approve the proposals to be presented to the Aptorum shareholders for